ArticleThe American journal of pathology1998
Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity.
Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 181 citations in OpenAlex.
- Functional Analysis of Membrane-Associated Scaffolding Tight Junction (TJ) Proteins in Tumorigenic Characteristics of B16-F10 Mouse Melanoma Cells.International journal of molecular sciences · 2024Article
- The role of endothelial junctions in the regulation of the extravasation of tumor cells. A historical reappraisal.Frontiers in oncology · 2024Review
- Reversion of breast epithelial polarity alterations caused by obesity.NPJ breast cancer · 2023Article
- Zonula Occludens Proteins Signaling in Inflammation and Tumorigenesis.International journal of biological sciences · 2023Review
- Research progress of Claudin-low breast cancer.Frontiers in oncology · 2023Review
- High expression of tight junction protein 1 as a predictive biomarker for bladder cancer grade and staging.Scientific reports · 2022Article
- RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers.Frontiers in oncology · 2021Article
- Role of Barrier Integrity and Dysfunctions in Maintaining the Healthy Gut and Their Health Outcomes.Frontiers in physiology · 2021Review
- Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma.Molecular therapy oncolytics · 2020Article
- Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening.Cancers · 2020Article
- IGF2BP3 and miR191-5p synergistically increase HCC cell invasiveness by altering ZO-1 expression.Oncology letters · 2020Article
- Distinct phenotypes of cancer cells on tissue matrix gel.Breast cancer research : BCR · 2020Article
- Dietary Puerarin Supplementation Alleviates Oxidative Stress in the Small Intestines of Diquat-Challenged Piglets.Animals : an open access journal from MDPI · 2020Article
- Review
- High expression of DLG3 is associated with decreased survival from breast cancer.Clinical and experimental pharmacology & physiology · 2019Article
- Host tissue determinants of tumour immunity.Nature reviews. Cancer · 2019Review
- Decreased expression of ZO-1 is associated with tumor metastases in liver cancer.Oncology letters · 2019Article
- Melatonin and non-small cell lung cancer: new insights into signaling pathways.Cancer cell international · 2019Review
- Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma.BMC cancer · 2018Article
- Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer.Cold Spring Harbor perspectives in biology · 2018Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Membrane-associated guanylate kinase homologs (MAGUKs) may play a role in cellular functions preventing tumorigenesis as indicated by the neoplastic phenotype caused by genetic loss of the MAGUK Dlg in Drosophila. To test this possibility, we examined the expression and subcellular localization of the tight junction MAGUK ZO-1, as well as the cell adhesion molecule E-cadherin, in paraffin-embedded breast cancer samples, using immunohistochemistry and confocal microscopy. As expected, normal tissue showed intense staining for ZO-1 at the position of the epithelial tight junctions, but this staining was reduced or lost in 69% of breast cancers analyzed (n = 48). In infiltrating ductal carcinomas (n = 38) there was a reduction in staining in 42% of well differentiated, in 83% of moderately differentiated and 93% of poorly differentiated tumors. ZO-1 staining was positively correlated with tumor differentiation (P = .011) and more specifically with the glandular differentiation of tumors (P = .0019). Reduction in ZO-1 staining was strongly correlated with reduced E-cadherin staining (P = 4.9 x 10(-5)). The results suggest that down-regulation of ZO-1 expression and its failure to accumulate at cell junctions may be causally related to cancer progression. To detect loss of heterozygosity, the ZO-1 gene tjp-1 was mapped relative to other markers in 15q13 and polymorphic markers flanking tjp-1 were identified. The marker D15S1019 showed loss of heterozygosity in 23% of informative tumors (n = 13). Loss of a tjp-1-linked marker suggests that genetic loss may, in some cases, be responsible for the reduction in ZO-1 expression in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.